semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 3.0-18.0,  Obstructive Sleep Apnea The study will all who are presenting for surgery to the main operating room, ambulatory surgical center or procedure center at Nationwide Children's Hospital  Emergency surgery and any caregiver or patient refusal
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 15.0-75.0,  Bronchial Asthma aged 15-75 2. first diagnosed corresponding to the diagnostic standards established by Asthma Committee, Respiratory Society, Chinese Medical Association, or previously diagnosed asthma without regular treatment 3. Mch bronchial provocation test is positive 4. the chest X-ray is normal  accompanied by other disease of respiratory system 2. combined with serious illness of other system, such as myocardial infarction, severe arrhythmia, malignant tumors and so on 3. women with pregnancy or lactation
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 2.0-16.0,  Asthmatic Attack Diagnosis of asthma  Active Cardiac Disease Speaks language other than English or Spanish
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-89.0,  Breast Cancer Patients who are scheduled to undergo therapeutic or prophylactic mastectomy with immediate placement of tissue expanders and have a strong family history or hereditary cancer 2. Age ≥ 18 years 3. Zafirlukast is pregnancy category B. There are no adequate and well-controlled trials in pregnant women. Therefore, the effects of zafirlukast on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception: 2 methods of birth control, prior to study entry ad for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. 4. Ability to understand a written informed consent document, and the willingness to sign it 5. At least 4 weeks post-completion of chemotherapy 6. Adequate organ function within 14 days start of study start: 1. Absolute neutrophil count (ANC) ≥ 1.5 X 10^9/L 2. Hemoglobin (Hgb) ≥9g/dL 3. Platelets (plt) ≥ 100 x 10^9/L 4. Potassium within normal range, or correctable with supplements; 5. AST and ALT ≤2.5 x Upper Limit Normal (ULN) or ≤5.0 x ULN if liver tumor is present; 6. Serum total bilirubin ≤ 1.5 x ULN 7. Serum creatinine ≤ 1.5 x ULN, or 24-hr clearance ≥ 60ml/min  Any significant medical condition, laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study 2. Currently on a leukotriene inhibitor or used within the past 6 months 3. Prior chest wall radiation 4. Pregnant or breastfeeding 5. Hepatic impairment as defined by: • AST(SGOT) > 2.5X institutional ULN and ALT(SGPT) > 2.5X institutional ULN 6. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Influenza, Human Pneumonia Any resident of one of the 10 LTCF intervention facilities with two acute respiratory infection symptoms (rhinorrhea/runny nose, nasal congestion, sore throat, cough or fever)  None
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Severe Asthma Subject participation in the TASMA study Ability and willingness to provide informed consent Ability to comply with the study protocol  Subject participating in another clinical trial involving respiratory intervention which in the opinion of the investigator might interfere with the study
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Asthma Black or Hispanic based on self-identification (Hispanic if identify as both) Male and female, ages 18-75 years Ability to provide informed consent Clinical history consistent with asthma for > 1 year Prescribed ICS as daily maintenance therapy Participant must also have an ACT score of 19 or less, or a history of one or more exacerbations in the past year that required patient report of systemic corticosteroid use  Life expectancy less than one year Known allergy to the ICS inhaler used in the study Having COPD or other chronic lung disease other than asthma; with the exception of the following Dx of COPD in a never smoker without any other lung disease or any other disease that might cause airway obstruction such as: Cystic Fibrosis, Connective Tissue Disease, premature birth, organ transplantation, bronchiectasis, sarcoid, and obliterative bronchiolitis Dx of COPD in former smoker with normal PFTs done after the person quit smoking Dx of COPD in current smoker with normal PFTs done in past 24 months Dx of COPD IN OR with obstruction on PFTs: normal diffusing capacity in past 24 months and demonstrated reversibility of 12% or more at any time Regular systemic corticosteroid use daily or every other day for any reason-including asthma or other medical reasons Use of systemic corticosteroid, or visit to the doctor's office, emergency department (ED) or urgent care, or overnight hospitalization for an asthma exacerbation in the past month (can wait and re-check after one month) Use of biologics (injections or infusion medicines): with the exception of the following
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 45.0-80.0,  Copd Age 45 to 80 years Smoking history >10 pack-year Mild COPD subjects: Male or female individuals; post-bronchodilator forced expiratory volume in 1 s (FEV1) ≥80% of predicted normal and post-bronchodilator FEV1/forced vital capacity (FVC) ratio <0.70 Non-COPD subjects: Male or female individuals; post-bronchodilator FEV1 ≥80% of predicted normal and post-bronchodilator FEV1/FVC ratio ≥0.70  Unable to tolerate study procedures Unable to walk or cycle without assistance Dementia or cognitive disorder, which would prevent the participant from consenting the study or completing study procedures Major depressive disorder Locomotor disease that seriously limits exercise tolerance Untreated symptomatic peripheral artery disease Body Mass Index >40 kg/m2 Non-COPD significant pulmonary disease such as asthma; interstitial lung disease; sarcoidosis; tuberculosis; cystic fibrosis; diffuse bronchiectasis; and others Primary pulmonary hypertension Current lung cancer
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Severe Sepsis Common for ICU patients : Signed informed consent, Patient affiliated or entitled to a social security, aged over 18 years for blood donor voluntary : to weigh more than 50 kg for severe sepsis group : Sepsis with failure of at least one organ, severe sepsis for less than 72 hours, sepsis with bacteria S. aureus, S. pneumoniae or E. coli for uninfectious inflammatory syndrome group : patients operate since less than 24 hours of hip or knee surgery, Absence of systemic infection  failure to participate at the study Patients with a aspirin treatment has continued throughout severe sepsis Patients with an appropriate antibiotic therapy for more than 72 hours Patients with a platelet transfusion in the week before or 72 hours after a surgical gesture or the occurrence of sepsis Patients with the platelet account is less than 30 000 per cubic millimeter the day of the sampling Patients with a severe sepsis who had a surgical gesture previous week the All clinical sequelae or biological at the selection pregnant woman Patients with a treatment by platelet aggregation has continued throughout severe sepsis
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Asthma Exacerbation Acute asthma exacerbations presenting to the emergency room Peak expiratory flow rate at presentation <40% of predicted Enrolment within 90 minutes of the arrival to the ER Age 18-55 years old  History of chronic obstructive pulmonary disease Clinical evidence to suggest a non-asthmatic cause of bronchospasm as determined by the treating physician Clinical evidence of acute coronary syndrome Respiratory failure requiring mechanical ventilation either invasive or non-invasive Tachyarrhythmia other than sinus Agitated or uncooperative Inability to provide informed consent
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Asthma Quality of Life Male and Female Patients about to start treatment with the inhaled combination of budesonide and formoterol fumarate dihydrate at doses 100 / 6mcg, 200 / 6mcg, 400/12 mcg, through Elpenhlaler device Regular treatment of asthma, wherein the administration of the combination (inhaled corticosteroid and long-action beta2-agonist) is appropriate Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled beta2-agonists short-acting Patients who signed Informed Consent Patients eligible to follow the study procedures  Patients who will be treated out of SpC Patients without Informed Consent Patients not eligible to follow the study procedures
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 8.0-16.0,  Asthma Children aged 8-16 years Patient with severe asthma (maximum expiratory flow <50%) Patient admitted to pediatric emergency Patient who has agreed to participate, as well as the parents or legal guardian  Chronic respiratory failure, infectious disease, heart disease Refusal to participate in the study No affiliation to a social security scheme (beneficiary or beneficiary) Immediate intubation
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 6.0-18.0,  Asthma in Children Age: More than or equal to 6 years old 2. Fulfilling the diagnosis of asthma or cough variant asthma (CVA) based on the guideline of China. 3. The patients cooperated very well with the doctors to perform lung function test. Asthma is defined as fulfilling followings 1-4 or 4 and 5: 1. History of variable respiratory symptoms: wheezing, shortness of breath, chest tightness, and coughing. Symptoms are often worse at night or upon awakening, and often triggered by exercise, laughter, allergens, or cold air, viral infections. 2. At onset, scattered wheeze in the lungs is heard with prolonged expiratory time. 3. The above symptoms and signs were efficient for anti-asthma, or alleviates voluntarily. 4. Exclusive of other diseases with wheezing, shortness of breath, chest tightness, and coughing. 5. If the manifestation is non-typical, fulfilling one of the followings Documented airflow limitation： 1. Positive BD reversibility test: Increase in FEV1 of >12% from baseline, 15 minutes after inhalation of 200-400 μg albuterol; 2. Significantly increased in lung function after anti-inflammatory treatment; 3. Increase in FEV1 of >12%, after 4 to 8 weeks of treatment with inhaled corticosteroids and (or) anti-leukotrienes Positive bronchial challenge test Excessive variability in twice-daily PEF over 2 weeks: Average daily diurnal PEF variability >13%. Cough variant asthma (CVA) is defined as fulfilling following: 1. Cough at least 4 weeks without sputum and wheeze, worsening at night or upon awakening; 2. No symptoms of infection, or no effect on long term antibiotic treatment; 3. The symptoms and signs were efficient for anti-asthma treatment; 4. Exclusive of other diseases causing wheeze; 5. Positive exercise challenge test and (or) average daily diurnal PEF variability >13%; 6. Individual or primary, secondary relatives with allergic history, or positive allergen detection  Subject will be excluded if she or he has one of the following: 1. congenital heart disease; 2. heart failure; 3. liver failure or renal insufficiency; 4. kidney disease; 5. connective tissue disease; 6. immunodeficiency; 7. tumor; 8. a history of hypertension or diabetes mellitus
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 21.0-99.0,  Severe Sepsis All adult patients (>18 years old) admitted to ICU plus Severe sepsis defined as 2 or more or the following Temperature >38oC or < 36oC Heart rate > 90 beats per min Respiratory rate >20 breaths per min or PaCO2 <32 mmHg White cell count > 12,000/microL or < 4,000/microL PLUS presence or presumed presence of infection PLUS evidence of organ dysfunction as defined by either of the following Hemodynamic: Hypotension = systolic blood pressure (SBP) 40 mm Hg or mean arterial pressure (MAP) < 65 mm Hg; or on vasopressors Hyperlactatemia: Serum lactate >/= 2 mmol/L (18 mg/dL)  >48hr from admission to ICU Patients who are not expected to survive >48hrs by the managing team Refusal to consent to study Allergic to glutamine or its constituents Absolute contraindication to enteral nutrition or the need to initiate parenteral nutrition Patients with a primary admission diagnosis of burns (>30% body surface area) Patients whose weight <40kg or >200kg Previous randomization to this study Enrolled in a related ICU interventional nutrition study Pregnant patients or lactating mothers with the intent to breastfeed
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 6.0-18.0,  Spinal Muscular Atrophy Type 3 Diagnosis of type III spinal muscular atrophy Be able to stand on the vibration platform with or without support Be able to undertake clinical examination and DXA evaluation Informed consent by the participant's parent/ guardian  There is a history of fracture within 8 weeks of enrolment of the present study and acute thrombosis, muscle or tendon inflammation, renal stones, discopathy or arthritis as reported by their parent/ guardian There is a history of using any of the following medications, regardless of dose, for at least 1 month, within 3 months of enrolment into the present study: anabolic agents, or growth hormone